|
| Wednesday, September 23, 2020 |
|
|
Eisai and Merck Present First-Time Data From Two Studies Evaluating KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020 |
| Results from LEAP-004 (Abstract #LBA44) and LEAP-005 (Abstract #LBA41) were accepted as late-breaking abstracts and are being presented in proffered paper presentations at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. more info >> |
|
| Friday, September 18, 2020 |
|
|
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020 |
| Eisai Co., Ltd. has announced that the latest results from the cohort targeting patients with HER2-negative breast cancer in phase I clinical trial for the new liposomal formulation (E7389-LF) of the in-house discovered anti-cancer treatment Halaven were presented (abstract number: 346P) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. more info >> |
|
| Thursday, September 17, 2020 |
|
|
Eisai Establishes Pharma Sales Subsidiary in Vietnam |
| Eisai Co., Ltd. announced today that it has established a new pharmaceutical sales subsidiary in Ho Chi Minh City, the Socialist Republic of Viet Nam, which will be named Eisai Vietnam Co., Ltd., Eisai Vietnam is a wholly-owned subsidiary of Eisai. more info >> |
|
| Friday, September 11, 2020 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020 |
| Eisai Co., Ltd. announced today that a series of abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19 to 21, 2020. more info >> |
|
| Monday, September 7, 2020 |
|
|
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma |
| Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020. more info >> |
|
| Tuesday, August 25, 2020 |
|
|
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream |
| Eisai conducted a survey of 1,000 women in their 40s to 50s in April 2020. As a result, it was found that approximately 70% of the subjects felt that the dryness of their skin and/or the dry skin expanse had increased compared to its condition five years ago. more info >> |
|
|
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020) |
| Eisai Co., Ltd. announced today that a total of 10 presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGOTM CIV) will be given at the 34th annual meeting of the Associated Professional Sleep Societies (SLEEP 2020), to be held virtually from August 27 to 30, 2020. more info >> |
|
| Friday, July 31, 2020 |
|
|
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan |
| In June 2020, LENVIMA received orphan drug designation in Japan for unresectable thymic carcinoma. more info >> |
|
| Wednesday, July 22, 2020 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020 |
| Eisai Co., Ltd. announced today that the company will conduct a total of 9 presentations, including the latest data of the investigational anti-amyloid beta (Aβ) protofibril antibody BAN2401, at the Alzheimer's Association International Conference (AAIC) to be held virtually from July 27 to 31, 2020. more info >> |
|
| Monday, July 20, 2020 |
|
|
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project |
| Allm Inc., Tokyo Medical and Dental University and Eisai Co., Ltd. announced that their jointly submitted study and development project has been selected by the Japan Agency for Medical Research and Development (AMED). more info >> |
|
|
|
